InterMune has posted a net loss of $24.28m for the third quarter 2010, or $0.44 loss per diluted share, compared to net loss of $8.77m, or $0.19 loss per diluted share, for the comparable period in 2009.
Loss from operations was $22.25m, compared to $6.04m for the comparable period in 2009.
For the nine months ended 30 September 2010, InterMune has posted net revenues of $17.63m, compared to $42.09m for the year ago period.
InterMune has posted a net loss of $83.71m, or $1.55 loss per diluted share for the nine months ended 30 September 2010, compared to net loss of $87.44m, or $2 loss per diluted share, for the year ago period.
The company’s loss from operations was $78.41m, compared to $74.57m for the year ago period.
InterMune CEO and president Dan Welch said that earlier this month they announced the sale of their rights to Danoprevir to Roche for $175m, a non-dilutive cash infusion that provides the financial strength and flexibility to independently pursue the registration and commercialisation of Pirfenidone.
"Our marketing authorisation application (MAA) for Pirfenidone is proceeding on schedule and on 15 October we submitted our responses to the CHMP’s Day 120 List of Questions," Welch said.
"We continue to anticipate a decision on the Pirfenidone MAA from the European authorities in the first half of 2011."